Ivacaftor · Kalydeco

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Cystic Fibrosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Cystic fibrosis with gating or R117H CFTR mutations (monotherapy) and in combination regimens
Product first approved 2012EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
Cystic Fibrosis
NCT03068312 · Vertex Pharmaceuticals Incorporated
2017-07-18 – 2018-12-18 · Cystic Fibrosis
What this study did
NCT02934698 · Medical University of South Carolina
2016-11-01 – 2018-05 · Cystic Fibrosis
What this study did
NCT02742519 · Vertex Pharmaceuticals Incorporated
2016-05 – 2017-08 · Cystic Fibrosis
What this study did
NCT01707290 · Vertex Pharmaceuticals Incorporated
2013-02 – 2016-04 · Cystic Fibrosis
What this study did
NCT01946412 · Vertex Pharmaceuticals Incorporated
2013-12 – 2015-12 · Cystic Fibrosis
What this study did
NCT01117012 · Vertex Pharmaceuticals Incorporated
2010-07 – 2014-05 · Cystic Fibrosis
What this study did
NCT01705145 · Vertex Pharmaceuticals Incorporated
2013-01 – 2014-03 · Cystic Fibrosis
What this study did
NCT01614470 · Vertex Pharmaceuticals Incorporated
2012-07 – 2013-10 · Cystic Fibrosis
What this study did
NCT01614457 · Vertex Pharmaceuticals Incorporated
2012-07 – 2013-10 · Cystic Fibrosis
What this study did
Phase 2 (7)
Cystic Fibrosis
NCT01685801 · Vertex Pharmaceuticals Incorporated
2012-09 – 2014-04 · Cystic Fibrosis
What this study did
NCT00953706 · Vertex Pharmaceuticals Incorporated
2009-09 – 2013-05 · Cystic Fibrosis
What this study did
NCT01161537 · Vertex Pharmaceuticals Incorporated
2010-10 – 2013-02 · Cystic Fibrosis
What this study did
NCT01262352 · Vertex Pharmaceuticals Incorporated
2011-01 – 2011-11 · Cystic Fibrosis
What this study did
NCT00457821 · Vertex Pharmaceuticals Incorporated
2007-05 – 2008-08 · Cystic Fibrosis
What this study did
Other / comorbidity
NCT04066751 · University of Alabama at Birmingham
2021-12-01 – 2024-10-31 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03085485 · University of Alabama at Birmingham
2017-03-16 – 2022-09-30 · Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
What this study did
Phase 1 (9)
Cystic Fibrosis
NCT02015507 · Vertex Pharmaceuticals Incorporated
2014-01 – 2014-02 · Cystic Fibrosis
What this study did
NCT01216046 · Vertex Pharmaceuticals Incorporated
2010-10 – 2011-05 · Cystic Fibrosis
What this study did
NCT01208285 · Vertex Pharmaceuticals Incorporated
2010-09 – 2010-12 · In Development for Cystic Fibrosis
What this study did
NCT01153542 · Vertex Pharmaceuticals Incorporated
2010-06 – 2010-08 · In Development for Cystic Fibrosis
What this study did
NCT01060566 · Vertex Pharmaceuticals Incorporated
2010-02 – 2010-04 · Cystic Fibrosis
What this study did
NCT01018368 · Vertex Pharmaceuticals Incorporated
2009-11 – 2010-03 · Cystic Fibrosis
What this study did
NCT00966602 · Vertex Pharmaceuticals Incorporated
2009-09 – 2009-12 · Cystic Fibrosis
What this study did
Other / comorbidity
NCT03439865 · University of Alabama at Birmingham
2019-05-02 – 2027-05-01 · Chronic Rhinosinusitis (Diagnosis)
What this study did
NCT02135432 · University of Alabama at Birmingham
2015-05 – 2015-11 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 4 (3)
Cystic Fibrosis
NCT03256799 · University of Alabama at Birmingham
2017-03-17 – 2018-02-16 · Cystic Fibrosis
What this study did
NCT01937325 · The Alfred
2014-02 – 2016-12 · Cystic Fibrosis
What this study did
Other / comorbidity
NCT03251911 · University of Alabama at Birmingham
2020-01-01 – 2022-02-01 · Chronic Bronchitis
What this study did
Early phase / not applicable (2)
Cystic Fibrosis
NCT02310789 · Richard Barry Moss
2015-07-31 – 2017-08-23 · Cystic Fibrosis
What this study did
NCT01784419 · University of California, San Francisco
2013-10 – 2015-12 · Cystic Fibrosis
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Phase 2 (2)
Cystic Fibrosis
Other / comorbidity
NCT02871778 · Parion Sciences
2016-08 – 2018-11-20 · Primary Ciliary Dyskinesia
What this study did
Phase 1 (3)
Other / comorbidity
NCT05968612 · Qanatpharma Canada LTD
2023-11-17 – 2023-12-18 · Healthy Volunteer
What this study did
NCT02599792 · Concert Pharmaceuticals
2015-11 – 2016-04 · Healthy
What this study did
NCT02392702 · Concert Pharmaceuticals
2015-03 – 2015-09 · Healthy
What this study did
Studied as part of a combination product (44)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (22)
Cystic Fibrosis
NCT05331183 · Vertex Pharmaceuticals Incorporated
2022-11-23 – 2027-04-06 · Cystic Fibrosis
What this study did
NCT05882357 · Vertex Pharmaceuticals Incorporated
2023-06-27 – 2025-09-04 · Cystic Fibrosis
What this study did
NCT04235140 · Vertex Pharmaceuticals Incorporated
2020-02-24 – 2023-08-22 · Cystic Fibrosis
What this study did
NCT05274269 · Vertex Pharmaceuticals Incorporated
2022-05-09 – 2023-07-05 · Cystic Fibrosis
What this study did
NCT04545515 · Vertex Pharmaceuticals Incorporated
2021-01-11 – 2023-03-24 · Cystic Fibrosis
What this study did
NCT05111145 · Vertex Pharmaceuticals Incorporated
2022-01-14 – 2022-12-20 · Cystic Fibrosis
What this study did
NCT03601637 · Vertex Pharmaceuticals Incorporated
2018-09-07 – 2021-10-29 · Cystic Fibrosis
What this study did
NCT04353817 · Vertex Pharmaceuticals Incorporated
2020-06-19 – 2021-05-17 · Cystic Fibrosis
What this study did
NCT04105972 · Vertex Pharmaceuticals Incorporated
2019-10-03 – 2020-07-24 · Cystic Fibrosis
What this study did
NCT02544451 · Vertex Pharmaceuticals Incorporated
2015-08 – 2020-04 · Cystic Fibrosis
What this study did
NCT03125395 · Vertex Pharmaceuticals Incorporated
2017-05-12 – 2019-07-17 · Cystic Fibrosis
What this study did
NCT02953314 · Vertex Pharmaceuticals Incorporated
2016-11 – 2018-09 · Cystic Fibrosis
What this study did
NCT03150719 · Vertex Pharmaceuticals Incorporated
2017-05-24 – 2018-08-09 · Cystic Fibrosis
What this study did
NCT02797132 · Vertex Pharmaceuticals Incorporated
2016-05 – 2017-09 · Cystic Fibrosis
What this study did
NCT02390219 · Vertex Pharmaceuticals Incorporated
2015-03 – 2016-10 · Cystic Fibrosis, Advanced Lung Disease
What this study did
NCT02514473 · Vertex Pharmaceuticals Incorporated
2015-07 – 2016-09 · Cystic Fibrosis
What this study did
NCT01931839 · Vertex Pharmaceuticals Incorporated
2013-10 – 2016-04 · Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
What this study did
NCT01897233 · Vertex Pharmaceuticals Incorporated
2013-07 – 2015-10 · Cystic Fibrosis
What this study did
NCT01807923 · Vertex Pharmaceuticals Incorporated
2013-05 – 2014-04 · Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
What this study did
NCT01807949 · Vertex Pharmaceuticals Incorporated
2013-04 – 2014-04 · Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
What this study did
Phase 2 (8)
Cystic Fibrosis
NCT03625466 · Vertex Pharmaceuticals Incorporated
2018-08-10 – 2021-10-07 · Cystic Fibrosis
What this study did
NCT04006873 · Nottingham University Hospitals NHS Trust
2019-09-03 – 2020-10-29 · Cystic Fibrosis
What this study did
NCT02730208 · Vertex Pharmaceuticals Incorporated
2016-09 – 2018-07 · Cystic Fibrosis
What this study did
NCT03061331 · Vertex Pharmaceuticals Incorporated
2017-01-31 – 2017-10-04 · Cystic Fibrosis
What this study did
NCT02508207 · Vertex Pharmaceuticals Incorporated
2016-02 – 2017-06 · Cystic Fibrosis
What this study did
NCT01225211 · Vertex Pharmaceuticals Incorporated
2010-10 – 2014-04 · Cystic Fibrosis
What this study did
Other / comorbidity
NCT04581408 · Istituto Auxologico Italiano
2021-06-15 – 2025-04-15 · Long QT Syndrome
What this study did
Phase 1 (6)
Cystic Fibrosis
NCT03029455 · Vertex Pharmaceuticals Incorporated
2016-11 – 2017-08 · Cystic Fibrosis
What this study did
NCT03486236 · Vertex Pharmaceuticals Incorporated
2016-07-20 – 2016-09-14 · Cystic Fibrosis
What this study did
NCT01910415 · Vertex Pharmaceuticals Incorporated
2013-06 – 2014-03 · Cystic Fibrosis
What this study did
NCT01768663 · Vertex Pharmaceuticals Incorporated
2013-01 – 2013-09 · Cystic Fibrosis
What this study did
NCT01899105 · Vertex Pharmaceuticals Incorporated
2013-07 – 2013-08 · Cystic Fibrosis
What this study did
Other / comorbidity
NCT01888393 · Vertex Pharmaceuticals Incorporated
2013-06 – 2013-11 · Hepatic Impairment, Healthy
What this study did
Phase 4 (6)
Cystic Fibrosis
NCT07148739 · Arkansas Children's Hospital Research Institute
2025-06-10 – 2030-12 · Cystic Fibrosis (CF)
What this study did
NCT04602468 · Royal College of Surgeons, Ireland
2020-09-03 – 2029-07-01 · Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication, Cystic Fibrosis Gastrointestinal Disease
What this study did
NCT07809867 · Istituto Giannina Gaslini
2026-09-18 – 2028-04 · Cystic Fibrosis (CF)
What this study did
NCT03624101 · University of Alabama at Birmingham
2018-12-01 – 2019-10-03 · Cystic Fibrosis
What this study did
NCT02875366 · Vertex Pharmaceuticals Incorporated
2016-09 – 2017-10 · Cystic Fibrosis
What this study did
NCT02823470 · Vertex Pharmaceuticals Incorporated
2016-06 – 2017-08 · Cystic Fibrosis
What this study did
Early phase / not applicable (2)
Cystic Fibrosis
NCT02858843 · Massachusetts General Hospital
2016-08-01 – 2018-05-01 · Cystic Fibrosis, Diabetes
What this study did
NCT02653027 · Massachusetts General Hospital
2018-01-01 – 2018-05-01 · Diabetes, Cystic Fibrosis
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (3)
Cystic Fibrosis
NCT06237335 · ReCode Therapeutics
2024-02-01 – 2026-11 · Cystic Fibrosis
What this study did
NCT04135495 · Eloxx Pharmaceuticals, Inc.
2019-11-25 – 2022-10-03 · Cystic Fibrosis
What this study did
NCT04126473 · Eloxx Pharmaceuticals, Inc.
2019-11-05 – 2022-04-06 · Cystic Fibrosis
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ivacaftor (Kalydeco): this drugApprovedSmall moleculeCFTRPartial signal
NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1)
NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7)
Elexacaftor / Tezacaftor / Ivacaftor (Trikafta)ApprovedSmall moleculeCFTR, CFTRReliable signal
NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results).
NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results).
Lumacaftor (Orkambi)ApprovedSmall moleculeCFTRReliable signalNo reviewed efficacy summary in this indication
Tezacaftor / Ivacaftor (Symdeko)ApprovedSmall moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek)ApprovedSmall moleculeCFTR, CFTRReliable signalNo reviewed efficacy summary in this indication
KB407Phase 1Gene therapy / editingCFTR (gene replacement)not yet gradedNo reviewed efficacy summary in this indication
VX-828Phase 1Small moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
LuvomeranDiscontinuedRNA / oligonucleotideCFTR (mRNA replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Kalydeco (Ivacaftor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 1Chronic Rhinosinusitis (Diagnosis)Recruiting
Est. primary completion 2027-04 · NCT03439865 · CT.gov ↗
What to watch

See the full readout calendar ↗